Drug Type Antibody drug conjugate (ADC) |
Synonyms |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC35H48ClN3O10S |
InChIKeyANZJBCHSOXCCRQ-FKUXLPTCSA-N |
CAS Registry139504-50-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 2 | - | - | |
Squamous Cell Carcinoma | Phase 2 | - | - | |
Non-Small Cell Lung Cancer | Phase 1 | US | 01 Feb 2017 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | US | 01 Feb 2017 | |
Triple Negative Breast Cancer | Phase 1 | US | 01 Feb 2017 |
NCT03094169 (AACR2019) Manual | Phase 1/2 | - | (nyuamznher) = G3 asymptomatic lipase elevation, G4 reversible thrombocytopenia olzofqmkll (zlgziyyrae ) View more | Positive | 01 Jul 2019 |